Scribd Logo
Upload

Welcome to Scribd!

  • 63 views

    Deeper Trial - Asco 2021

    Uploaded by

    Vuong Dinh Thy Hao
    The DEEPER trial compared the effectiveness of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as first-line treatments for metastatic colorectal cancer patients with RAS wild-type tumors. The randomized phase II study assessed depth of response, overall response rate, progression-free survival, and overall survival between the two treatment groups. The trial involved 87 institutions in Japan and analyzed toxicity outcomes.

    Copyright:

    Public Domain
    Download as PPTX, PDF, TXT or read online from Scribd

    Deeper Trial - Asco 2021

    Uploaded by

    Vuong Dinh Thy Hao
    63 views26 pages
    The DEEPER trial compared the effectiveness of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as first-line treatments for metastatic colorectal cancer patients with RAS wild-type tumors. The randomized phase II study assessed depth of response, overall response rate, progression-free survival, and overall survival between the two treatment groups. The trial involved 87 institutions in Japan and analyzed toxicity outcomes.

    Original Description:

    metastatic colorectal cancer - FOLFOXIRI- Cetuximab/ Bevacizumab

    Original Title

    Deeper trial- asco 2021

    Copyright

    © Public Domain

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The DEEPER trial compared the effectiveness of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as first-line treatments for metastatic colorectal cancer patients with RAS wild-type tumors. The randomized phase II study assessed depth of response, overall response rate, progression-free survival, and overall survival between the two treatment groups. The trial involved 87 institutions in Japan and analyzed toxicity outcomes.

    Copyright:

    Public Domain
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    63 views26 pages

    Deeper Trial - Asco 2021

    Uploaded by

    Vuong Dinh Thy Hao
    The DEEPER trial compared the effectiveness of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as first-line treatments for metastatic colorectal cancer patients with RAS wild-type tumors. The randomized phase II study assessed depth of response, overall response rate, progression-free survival, and overall survival between the two treatment groups. The trial involved 87 institutions in Japan and analyzed toxicity outcomes.

    Copyright:

    Public Domain
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 26

    The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic

    colorectal cancer with RAS wild-type tumors:


    <br />The DEEPER trial (JACCRO CC-13)

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Backgrounds

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Objectives

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Methods

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Methods

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Methods

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Methods

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    CONSORT diagram

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    CONSORT diagram

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Patient characteristics

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Patient characteristics (cont.)

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Treatment disposition

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Depth of Response <primary endpoint>

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Waterfall Plot (Depth of Response)

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Waterfall Plot (Depth of Response)

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Depth of Response by tumor location

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Overall Response Rate

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Early Tumor Shrinkage (ETS) Rate <br />at week 8

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Toxicity

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Toxicity

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Toxicity

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Progression-Free Survival in the FAS population

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Overall Survival in the FAS population

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Conclusion

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Acknowledgments to

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
    Institutions: JACCRO CC-13 Study Group <br />consists of 87 institutions

    Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

    You might also like